PubMed
Thymosin beta4: a multi-functional regenerative peptide (review)
Goldstein et al., 2012
Healing & RecoveryResearch OnlyC
TB-500 Fragment
TB4 Fragment
TB4-derived fragment used in repair protocols; limited direct human data.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 56
- Activity
- 84
Overall check-ins
Trackers & reports
Overview
About TB-500 Fragment
TB4-derived fragment used in repair protocols; limited direct human data.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- TB4 Fragment
- Self-reports
- 26
Community
What 26 users report
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
176
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
171
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
59
2+ mg
117
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 188 days · Based on 24 repeat reporters
Research
Cited research (3)
Source
PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein et al., 2010
PubMed
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias et al., 2026
Tools
Explore more
Explore
More ways to learn about TB-500 Fragment from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about TB-500 Fragment?
This page summarizes 26 anonymized self-reports from PeptIQ users who track TB-500 Fragment, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for TB-500 Fragment?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for TB-500 Fragment?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is TB-500 Fragment safe to use?
This wiki does not assess safety or recommend use. TB-500 Fragment is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of TB-500 Fragment?
This wiki summarizes observational community reports and linked citations for TB-500 Fragment. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for TB-500 Fragment for study-level context — not medical advice.
What is the legal status of TB-500 Fragment?
TB-500 Fragment is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of TB-500 Fragment?
Safety data quality for TB-500 Fragment varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on TB-500 Fragment?
This page links 3 indexed sources for TB-500 Fragment. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.